Imbruvica (Ibrutinib)

Imbruvica is a BTK inhibitor used in the treatment of B‑cell malignancies and related disorders.

• Chronic lymphocytic leukemia (CLL): reduces disease burden and prolongs progression‑free survival.
• Small lymphocytic lymphoma (SLL): improves response rates and delays need for additional therapy.
• Mantle cell lymphoma (MCL): achieves durable remissions in relapsed or refractory patients.
• Waldenström macroglobulinemia (WM): lowers IgM levels and controls disease activity.
• Marginal zone lymphoma (MZL): induces tumor regression and extends overall survival.
• Chronic graft‑versus‑host disease (cGVHD): mitigates immune‑mediated tissue damage and improves functional outcomes.

• Ibrutinib binds irreversibly to the active site of Bruton tyrosine kinase, a key enzyme in the B‑cell receptor signaling cascade. By blocking BTK, the drug inhibits downstream pathways that drive malignant B‑cell proliferation, survival, and migration, leading to reduced tumor growth and enhanced apoptosis of cancerous cells.

Imbruvica may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Diarrhea: mild to moderate watery stools.
• Bleeding: increased bruising or nosebleeds.
• Infections: upper respiratory or urinary tract infections.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: occasional upset stomach.
• Arthralgia: joint pain or stiffness.

Serious or Rare Side Effects

• Atrial fibrillation: irregular heart rhythm requiring medical attention.
• Severe hemorrhage: gastrointestinal or intracranial bleeding.
• Tumor lysis syndrome: rapid tumor cell breakdown with metabolic disturbances.
• Opportunistic infections: pneumonia or fungal infections.
• Hepatic toxicity: elevated liver enzymes or hepatitis.

When prescribing Imbruvica, clinicians should observe several precautionary measures to minimize risks.

• Monitor blood counts: regular CBC to detect cytopenias.
• Assess bleeding risk: avoid concomitant anticoagulants when possible.
• Evaluate cardiac function: baseline ECG and periodic monitoring for arrhythmias.
• Avoid strong CYP3A4 inhibitors: dose adjustments may be required.
• Use caution in hepatic impairment: consider dose reduction.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Imbruvica interacts with several medicines through CYP3A4 metabolism and platelet function modulation.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ibrutinib exposure.
• Anticoagulants (e.g., warfarin, rivaroxaban): heightened bleeding risk.
• Antiplatelet agents (e.g., aspirin, clopidogrel): additive hemorrhagic potential.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.

Moderate Interactions (Monitor Closely)

• Narrow‑therapeutic‑index CYP3A substrates (e.g., cyclosporine, tacrolimus): monitor levels.
• Moderate CYP3A inhibitors (e.g., erythromycin, fluconazole): consider dose adjustment.
• CYP3A inducers with moderate potency (e.g., phenytoin): observe clinical response.